Capital Group Private Client Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Group Private Client Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,070	Closed	-$425K	–	244
2025 Q4	$425K	Hold	1,070	–	–	0.01%	252
2025 Q3	$488K	Hold	1,070	–	–	0.01%	250
2025 Q2	$349K	Sell	1,070 -786	-42%	-$217K	﹤0.01%	266
2025 Q1	$501K	Sell	1,856 -39,669	-96%	-$10.2M	﹤0.01%	250
2024 Q4	$9.77M	Sell	41,525 -924	-2%	-$243K	0.09%	154
2024 Q3	$11.7M	Sell	42,449 -675	-2%	-$176K	0.11%	148
2024 Q2	$10.5M	Sell	43,124 -11,297	-21%	-$1.78M	0.1%	143
2024 Q1	$8.13M	Buy	54,421 +4,660	+9%	+$777K	0.08%	152
2023 Q4	$9.52M	Buy	49,761 +43,500	+695%	+$7.41M	0.1%	140
2023 Q3	$1.11M	Sell	6,261 -93	-1%	-$17.7K	0.01%	205
2023 Q2	$1.21M	Buy	+6,354	New	+$1.26M	0.01%	195

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Group Private Client Services's ALNY Position: Q1 2026 in Review

Capital Group Private Client Services sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,070 shares — an estimated $425K sold.

Capital Group Private Client Services first reported a position in ALNY in Q2 2023 and held it in 11 quarters. The position peaked at $11.7M in Q3 2024. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Capital Group Private Client Services reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Capital Group Private Client Services sold 1,070 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $425K.
Capital Group Private Client Services first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 11 quarters.
Capital Group Private Client Services's Alnylam Pharmaceuticals position peaked at $11.7M in Q3 2024.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capital Group Private Client Services's 13F filing for Q1 2026, filed 13 May 2026.